Navigation Links
The Alliance for Regenerative Medicine forms Tissue Engineering and Biomaterials Committee
Date:12/13/2012

WASHINGTON, Dec. 13, 2012 /PRNewswire/ -- The Alliance for Regenerative Medicine (ARM) today announced the formation of a Tissue Engineering and Biomaterials Committee (TEBC). The TEBC has been established to assemble the companies, academic institutions, and organizations within the Alliance for Regenerative Medicine that develop and commercialize tissue engineered and biomaterial based technologies. The primary purpose of the TEBC is to develop a better understanding of the key barriers to translation and scale up of regenerative medicine technologies including challenges in efficient product design, pilot and scale up manufacturing, regulation, and reimbursement. In addition the TEBC will focus on building public awareness of this new field of medicine and an appreciation for its potential to transform healthcare.

Members of the TEBC will include private and public sector representatives involved in the field of tissue engineering.   Tissue engineered technologies are being developed as clinical therapeutics to improve biological functions primarily through the repair, restoration, or total replacement of tissue or organ and are also being developed and commercialized as 3D tissue models and micro-organs to provide better research tools for drug discovery and clinical diagnostics. The TEBC group will include experts from interdisciplinary technologies that utilize cells, biomaterials, growth factors, small molecules, scaffolds, and other therapeutic agents to affect tissue growth or regeneration. The Committee will be led by Sarah Haecker PhD, a member of ARM's senior staff.  Sarah has more than 20 years of experience in the industry and for the last seven years has specialized in working with companies in the tissue engineering sector.

"We will work to identify and capitalize on opportunities that accelerate product development and commercialization of these innovative regenerative medicine technologies," said Sarah Haecker. "The primary purpose of the TEBC is to determine the unique requirements which will, ultimately, advance and broaden the use of clinical tissue engineered paradigms world-wide."

"To successfully design, develop, and commercialize complex tissue engineered products, it is critical to bring together the leading experts in a multitude of disciplines and technology areas," said Robert Palay, co-chair of the TEBC and Chief Executive Officer of Cellular Dynamics International, Inc.  "I am excited to be working with this group which is strategically designed and uniquely qualified to best move the wide range of tissue engineered products forward."

"Tissue engineering has tremendous potential to treat patients suffering from the loss of tissues and organs," said Jennifer H. Elisseeff, co-chair of the TEBC and Professor, Wilmer Eye Institute and Department of Biomedical Engineering, Johns Hopkins University. "We have the ability to establish the critical early and robust communication between the product designers and clinicians to support the successful path through commercialization of these complex products." 

"Through the work of the TEBC, we hope to bring tissue engineered therapeutics to patients worldwide more quickly," said Michael Abecassis, MD, co-chair of the TEBC and Founding Director, Northwestern University Comprehensive Transplant Center.  "We intend to develop a better understanding amongst key stakeholders as to the requirements to develop a more predictable regulatory pathway and a rational reimbursement framework for tissue engineered and biomaterial based products."

Members of the Tissue Engineering and Biomaterials Committee:

Cellular Dynamics, Circle Biologics, Harvard Bioscience, Histogenics, InVivo Therapeutics, ISTO, JDRF, Johns Hopkins University, McGowan Institute for Regenerative Medicine, MiMedx, Nanofiber Solutions, Northwestern University Comprehensive Transplant Center, Northwestern University's Feinberg School of Medicine, New York Stem Cell Institute, Organogenesis, Organovo, Pfizer, Sanofi Genzyme, Shire Regenerative Medicine, Tengion, Texas Heart Institute, Wake Forest Institute for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.

 

Media Contact:
Michelle Linn
Linnden Communications
Phone: 508-362-3087

 


'/>"/>
SOURCE The Alliance for Regenerative Medicine
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
2. BioPower Operations Corporation Announces that FTZ Exchange Signs Strategic Alliance with Capacity 360, LLC and Tom Settineri
3. Ekahau - A Preferred Provider of Real-Time Location Solutions - Is Awarded an Agreement with the Premier Healthcare Alliance
4. iBio, Inc. and GE Healthcare form new global alliance
5. Afraxis and PsychoGenics Form Alliance to Offer Afraxis ESP Technology for Drug Discovery
6. Genomind to Participate in National Alliance on Mental Illness (NAMI) 2012 National Convention
7. Clean Energy Alliance and the Manufacturing Extension Partnership Announce New Collaboration
8. Economic Alliance of Greater Baltimore Inks Business Partnership with BioHealth Innovation to Bring Health and Life Sciences Research to Market
9. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
10. Donor Alliance Honors Families at the 2012 Donor Family Tribute
11. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... at four equities in the Biotech industry: Sangamo Therapeutics ... Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. ... st , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology ... downloading their free report at: ...
(Date:3/22/2017)... SANTA MONICA, Calif. , March 22, 2017 ... Council (MassMEDIC) are proud to announce their extended partnership ... Week will be headlined by the 21 st ... UBM,s BIOMEDevice Boston, taking place May 3-4, 2017. ... with Advanced Medical Technology Association (ADVAMED) President and ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced ... of their live events series, “Stem Cell Therapy: The Next Phase in the Evolution ... 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission to ...
Breaking Biology Technology:
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
Breaking Biology News(10 mins):